GW Pharmaceuticals (NASDAQ:GWPH) is one of the top marijuana stocks on the market right now. Its share price more than tripled over the last 12 months. Wall Street thinks shares of GW Pharmaceuticals could surge another 25% or more over the next 12 months.
But all of the biotech’s past success and future hopes could evaporate if one specific thing happens, even if GW wins regulatory approval for cannabinoid drug Epidiolex — as many expect it to. Here’s what that one thing is, and how likely it might be.
First things first
Before we end the suspense, let’s first examine why GW Pharmaceuticals currently claims a market cap of over $3 billion. It’s certainly not because of the company’s one drug on the market, Sativex. The cannabinoid drug approved in several countries outside the U.S. for spasticity due to multiple sclerosis